An interventional study of transcranial alternating current stimulation (tACS) and high-density electroencephalography (hdEEG) in Mild Cognitive Impairment, sponsored by Lucie Bréchet. Recruiting at 1 site in Switzerland. Open to participants aged 55 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-15.
Sponsored by Lucie Bréchet · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Cognitive Dysfunction with a site in Switzerland — 17 open to participants now, 21 under way, 3 of them phase 3. Cognitive Dysfunction · Switzerland.
Among the 61 studies in Cognitive Dysfunction with a site in Switzerland, this one is the 33rd largest by planned enrollment of the 48 interventional ones that give a count, is one of 9 that started in 2023, is one of 38 with no phase, reaches primary completion later than 11 of the 20 other live ones, and was the 39th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →17 of the 61 studies in Cognitive Dysfunction with a site in Switzerland are open now. Recruiting first, the newest first:
Boris Quednow · Sites in Switzerland
Ages 20–50
University of Zurich · Sites in Switzerland
Ages 18+
University of Bern · Sites in Switzerland
Ages 60–85
Mclean Hospital · Sites in Switzerland, United States
Ages 18–35
Société des Produits Nestlé (SPN) · Sites in Switzerland, France, Germany and 3 more countries
Ages 60+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 55 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 7 · Phase 4 2
First in 2010; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 56 across the 48 interventional studies, 96 across the 13 observational. Of the 33 that completed or were terminated, 4 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 61 have an industry lead sponsor. The 10 most frequent:
Lucie Bréchet is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Lucie Bréchet has 2 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
5 of the studies in Cognitive Dysfunction with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06191965Phase 3Mclean HospitalMitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction | 2027-01-31 |
| NCT06207942Region SkaneStepcare Extended Follow-up Substudy | 2027-01 |
| NCT05710549Lucie BréchetUnderstanding Brain Mechanisms Involved in Autobiographical Memory | 2027-05-01 |
| NCT07532460Boris QuednowThe Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users | 2027-08 |
| NCT05708001Lucie BréchetImprovement of Memory in Mild Cognitive Impairment | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 61 studies in Cognitive Dysfunction with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Clinical Trial will systematically examine the feasibility of remote, caregiver-led tACS for older adults with memory deficits and evaluate whether repeated tACS leads to sustained improvement of neuronal activity and memory functions.
The proposed investigation will systematically examine the feasibility and efficacy of remote, caregiver-led tACS for older adults with memory decline. This study will provide data to support the safety and effectiveness of home-based tACS in this population and will lead to future research to increase access to tACS as a part of memory decline prevention and treatment for older adults.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Mild Cognitive Impairment (MCI) patients
Caregiver
Exclusion Criteria:
Mild Cognitive Impairment (MCI) patients
Caregiver
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The randomized, sham-controlled, parallel-arm, double-blind clinical trial will include 4 weeks of daily, home-based stimulation sessions. MCI patients will be randomly assigned to the active or sham group.
Device: transcranial alternating current stimulation (tACS)
At the baseline and after 4 weeks, MCI patients will be evaluated in the laboratory using hdEEG.
Device: high-density electroencephalography (hdEEG)
At the baseline and after 4 weeks, MCI patients will be evaluated in the laboratory using MoCA.
Diagnostic Test: Montreal Cognitive Assessment (MoCA)
tACS will be delivered by a battery-driven current stimulator Starstim SS32 (Neuroelectrics) through surface Ag/AgCl electrodes placed into holes of a neoprene cap corresponding to the international 10/20 EEG system. Gel (Parker Lab, Inc.) will be applied to optimize signal conductivity and lower impedance. Two tACS (active and sham) conditions will be applied in randomized order. 40 Hz tACS will be delivered to different brain areas of the memory network. We will employ a multielectrode montage based on electric field modeling using the individual MRI to optimally reach the target areas. The maximum injected current per electrode is 2mA and the overall maximal current is 4mA to generate an average electric field of 0.25 V/m.
EEG will be recorded with a 257-channel EEG system. An EEG net is applied at once on the head with evenly spaced sensors that provide full scalp coverage, including the cheek. The net contains Ag/Ag-Cl electrodes that are interconnected by thin rubber bands and contain small sponges soaked with saline water that touch the participant's scalp surface directly. Net application takes about 10 min to derive to impedances of \<30 kOhms. EEG is recorded with 1 kHz and band-pass filtered between DC-200 Hz. Vertex electrode Cz is used as an acquisition reference.
Clinical Evaluation and Cognitive Assessment - to characterize the level of dementia and changes in cognitive status measured at the baseline and after 4 weeks of gamma/sham tACS intervention, and in a follow-up 3 months after the stimulation using MoCA.
cognitive status measured by Montreal Cognitive Assessment (MoCA)
The primary objective is to characterize cognitive status at baseline and after 4 weeks of the home-based stimulation intervention.
Time frame: baseline, after 4 weeks
modulation of gamma activity assessed with high-density EEG
The secondary objective is to assess with hdEEG any changes in gamma power at baseline and after 4 weeks of the home-based stimulation intervention.
Time frame: baseline, after 4 weeks,
Started Feb 2023 (actual). Primary completion is estimated for Sep 2027, 55 months after the start.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 55 months is above that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lucie Bréchet